Eczema drug Dupilumab's skin gene secrets revealed in small study
NCT ID NCT03293030
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how the eczema drug dupilumab (Dupixent) affects immune cells and genes in the skin. Seventeen adults with moderate-to-severe eczema took the drug, and researchers measured changes in skin samples over 12 weeks. The goal was to understand the biological effects of dupilumab on eczema lesions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dupilumab (Dupixent)
- What this could lead to
- If successful, this could help explain how dupilumab works in the skin to improve eczema treatment.
- What could go wrong
- This was a very small study with only 17 people and no comparison group, so results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, 94118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?